Wells Fargo Maintains Overweight on WAVE Life Sciences, Lowers Price Target to $13

Wells Fargo analyst Benjamin Burnett has maintained an Overweight rating on WAVE Life Sciences (NASDAQ: WVE) but has reduced the price target from $27 to $13. This adjustment reflects a significant decrease in the expected valuation of the company.